therapy start-up ONK Therapeutics has raised another $21.5 million as it continues efforts to develop technology that enhances natural killer cells in the body’s immune system to target cancers.
It is currently targeting three oncology areas – relapsed multiple myeloma and acute myeloid leukaemia, both of which are cancers of the blood, and solid cancer tumours in areas including ovarian, breast and lung cancers.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: